×
Back to Agenda
Session 10: Advanced Therapies
Session Chair(s)
Robert L. Levin, MD
Lead Medical Officer for Pharmacovigilance Strategy, FDA, United States
Session Chair
Speaker(s)
James Wabby, MHS
VP, Head of Regulatory Strategy, Emerging Technologies and Combination Products, AbbVie, United States
Precision Medicine, Pharmacovigilance, and Risk Management
Gerald L. Messerschmidt, MD, FACP
Chief Medical Officer, Precision Oncology, United States
Pharmacovigilance and Risk Management of Advanced Therapies
Dina Tresnan, DVM, PhD
SSRM Disease Area Cluster Lead - Oncology, Pfizer Inc, United States
Safety Considerations for Regenerative Medicine
Abla Creasey, PhD
Vice President Therapeutics Development, California Institute of Regenerative Medicine, United States
Have an account?